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Objectives. Cytoplasmic inclusions containing TDP-43 are a pathological hallmark of several 
neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia. TDP-43 is an RNA binding protein involved in gene regulation through control of 
RNA transcription, splicing and transport. However, the function of TDP-43 in the nervous 
system is largely unknown and its role in the pathogenesis of ALS is unclear. The aim of this 
study was to identify genes in the central nervous system that are regulated by TDP-43. Methods. 
RNA-immunoprecipitation with anti-TDP-43 antibody, followed by microarray analysis (RIP-
chip), was used to isolate and identify RNA bound to TDP-43 protein from mouse brain. Results. 
This analysis produced a list of 1,839 potential TDP-43 gene targets, many of which overlap 
with previous studies and whose functions include RNA processing and synaptic function. 
Immunohistochemistry demonstrated that the TDP-43 protein could be found at the presynaptic 
membrane of axon terminals in the neuromuscular junction in mice. Conclusions. The finding 
that TDP-43 binds to RNA that codes for genes related to synaptic function, together with the 
localisation of TDP-43 protein at axon terminals, suggest a role for TDP-43 in the transport of 
synaptic mRNAs into distal processes. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is characterised by ubiquitinated cytoplasmic, nuclear, and 
neuritic inclusions in the motor neurons of the brain and spinal cord. The discovery that TDP-43 
is a major component of these inclusions (1, 2) was a key breakthrough in the understanding of 
ALS as it suggests that TDP-43 functions in important neuronal activities, the impairment of 
which would lead to degeneration of specific neuronal populations. TDP-43 is a heterogeneous 
nuclear ribonucleoprotein (hnRNP) that is encoded by the TARDBP gene (3). The discovery of 
mutations within TARDBP in familial and sporadic ALS patients (4, 5) has established a clear 
pathogenic link between TDP-43 and ALS. Approximately 40 different TARDBP missense 
mutations have now been reported in ALS, including three cases of ALS plus concomitant 
frontotemporal lobar degeneration (6). However, although TDP-43 has been implicated in a 
diverse range of metabolic and physiological processes, including RNA transport and splicing, 
mutations have provided no insight into why motor neurons die in ALS patients.  
 
TDP-43 binds to UG-rich repeats in target RNAs, facilitating mRNA splicing and transport. The 
ability of TDP-43 to bind RNA, the presence of a nuclear localisation signal, and a strong 
nuclear export sequence indicate that TDP-43 has a role in nuclear-cytoplasmic shuttling of 
mRNAs (7). The observation of TDP-43 within RNA granules in developing brain further 
suggests that TDP-43 may be involved in mRNA transport (8). As DNA is confined to the 
nucleus, appropriate subcellular trafficking of mRNA plays an important role in determining the 
biological activities of the transcripts, particularly in neurons where the distance between the 
nucleus and subcellular compartments can be significant. In addition to its role in RNA transport, 
TDP-43 also regulates splicing by binding to UG-rich sequences within pre-mRNA (9). Tissue-
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specific alternative mRNA splicing is essential for the expression of functionally different gene 
products from a single gene, and various human diseases are known to be caused by disruption 
of the splicing machinery (10). 
 
There is increasing evidence that ALS is a disorder of RNA metabolism. RNA oxidation 
precedes the development of overt motor neuron damage in transgenic mice expressing ALS-
associated mutations in superoxide dismutase -1 (SOD1) (11). Mutations in FUS/TLS, an RNA 
binding protein with similar structure to TDP-43, have been associated with both frontotemporal 
dementia (FTD) and ALS (6, 12).  Similarly, mutations in SETX, a DNA/RNA helicase involved 
in RNA transcription and translation, have been linked with cerebellar ataxia, progressive motor 
neuropathy and more recently with ALS (6, 13). Another well-established example of altered 
RNA processing in neurodegeneration is loss of the SMN (survival of motor neuron) RNA 
binding protein in spinal muscular atrophy, a form of motor neuron disease with earlier onset 
than ALS (14). Other ALS-associated genes involved in RNA processing pathways include the 
ribonuclease protein, angiogenin (ANG) (15), and elongator protein 3 (ELP3), a component of 
the RNA polymerase II complex (16). 
 
Even though most ALS patients do not have mutations in TDP-43 (but TDP-43 still forms 
aggregates) the loss of TDP-43 function and resulting disruption of RNA processing is likely to 
be a major contributor to the disease. This is supported by the fact that a transgenic mouse 
overexpressing mutant human TDP-43 does not develop cytoplasmic aggregates and yet motor 
neurons still degenerate, suggesting that aggregates are not the primary cause of degeneration 
(17). Furthermore, knockdown of TDP-43 in Drosophila (18) and zebrafish (19) leads to 
behavioural motor deficits and abnormal motor neuron morphology. We therefore hypothesise 
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that any dysfunction of TDP-43 (aggregation or mutation) will affect the RNA-binding ability of 
the protein and the subsequent regulation and processing of RNA transcripts needed for motor 
neuron function. 
 
An important step in understanding how TDP-43 causes ALS is identifying the RNA transcripts 
that TDP-43 regulates, followed by the production of a comprehensive map of RNA targets in 
normal nerve tissue. Recent reports have begun to identify the RNA targets of TDP-43 in the 
rodent brain, using a combination of RNA-immunoprecipitation followed by either direct 
sequencing (20-23) or microarray analysis (24). In the first report, cultured embryonic rat 
cortical neurons were used and the 4,352 genes identified were enriched for Gene Ontology 
terms related to synaptic function, RNA metabolism and neuronal development (20). In the 
second study, over 6,300 potential TDP-43 RNA targets were identified in the adult mouse brain 
(21). The main functional categories enriched in this second study also included synaptic 
function, as well as ion channel activity and transmembrane transporter activity. The study by 
Tollervey et al. (22) included a comparison between healthy and FTD post-mortem brain 
samples, which identified 59 transcripts with altered TDP-43 binding. In the final two studies, 
human neuroblastoma cell lines (23) and mouse motoneuronal cell lines (24) were analysed, with 
both studies identifying less than 200 RNA targets of TDP-43. In the current study, genome-wide 
analysis was performed to identify RNA bound to TDP-43 protein from total mouse brain tissue. 
Localisation of TDP-43 within axon terminals of the mouse neuromuscular junction was also 
examined.  
 
Material and Methods 
Animals and tissue preparation 
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Four 10-week-old C57BL/6J mice were euthanased and brain tissue harvested. Mouse brain 
tissue was homogenised in polysome lysis buffer supplemented with RNase and protease 
inhibitors as previously described (25). Following centrifugation at 15,000 x g for 15 minutes at 
4˚C to pellet large particles, the clear supernatant was used in subsequent IP experiments. Three 
samples were used in the microarray analysis and the fourth was used for TDP-43 target 
validation by RT-PCR. The University of Queensland Animal Ethics Committee approved all 
experiments.   
 
RNA immunoprecipitation (RIP) and western blotting 
250 μg of protein lysate from each mouse brain was used for IP with 5µg of either rabbit anti-
TDP-43 antibody (Abcam, Waterloo, Australia) or normal rabbit IgG (Sigma Aldrich, Sydney, 
Australia). The antibodies were incubated with the lysate overnight at 4˚C, after which 50 µL of 
protein G Dynabeads (Invitrogen, Mulgrave, Australia) were added and the solution incubated 
for 1 hour at 4°C with rotation. Following several washes with washing buffer (Invitrogen) 20 
µL of the protein-bead complex was eluted using 10 µL of elution buffer (Invitrogen) and 
separated on a 10% NuPage Bis-Tris gel (Invitrogen). RNA was isolated from the remaining 30 
µL of protein-bead complex using TRIzol reagent (Invitrogen) followed by DNase I treatment 
(Ambion, Mulgrave, Australia).    
 
Microarray analysis 
The TDP-43 and IgG immunoprecipitated RNA from three mice was converted to cDNA, 
fragmented, then biotin labelled using the WT cDNA Synthesis & Amplification Kit and 
Terminal Labeling Kit (Affymetrix, Santa Clara, CA) for Affymetrix GeneChip Mouse Gene 1.0 
ST arrays and the 3’-IVT Expression Analysis Kit (Affymetrix) for GeneChip Mouse 430 arrays. 
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Labelled RNA was hybridised to arrays overnight, washed then scanned using the Affymetrix 
GeneChip Scanner. Successful hybridisation to the microarray was determined using Expression 
Console software (Affymetrix) and the data (.CEL files) transferred to Partek Genomics Suite for 
statistical analysis. TDP-43 and IgG immunoprecipitated RNA samples were each hybridised to 
3 GeneChip Mouse Gene 1.0 ST and 3 GeneChip Mouse 430 (n = 6 for each group).  Raw data 
files have been submitted to ArrayExpress (accession: E-MEXP-3500). 
 
Bioinformatic analysis 
Data analysis was performed using Partek Genomics Suite (Partek Inc. USA) in strict adherence 
to the MIAME (Minimum Information on Microarray Experiment) standards. Steps performed in 
Partek included 1) robust microarray averaging (RMA) to normalise the data, 2) principal 
component analysis (PCA) to check for sample outliers, 3) analysis of variance (ANOVA) to 
generate p values and finally, 3) generation of gene lists using the conditions p < 0.05 and fold 
change > 2. The gene lists generated by Partek were further analysed using Ingenuity Pathway 
Analysis (IPA) software (Ingenuity Systems, Redwood City, CA). IPA was used to assess the 
signalling and metabolic pathways, molecular networks, and biological processes that were most 
significantly represented in the microarray dataset.  The MEME suite was used to identify 
common sequence motifs shared among the binding partners (26). Gene Ontology (GO) 
enrichment analysis of the significant transcripts was carried out using FatiGO (27). 
 
TDP-43 target validation using RT (reverse transcriptase) PCR 
TDP-43 and IgG immunoprecipitated RNA (100 ng) was reverse transcribed using the 
SuperScript III kit (Invitrogen) to produce cDNA.  Primers used for amplification are listed in 
Supplemental file 1. PCR conditions for the experiment were: denaturation at 94˚C for 1 min; 10 
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cycles of denaturation at 94˚C for 30 s, annealing at 60˚C for 30 s, extension at 72 ˚C for 30 s; 25 
cycles of denaturation at 94˚C for 30 s, annealing at 55˚C for 30 s and extension at 72˚C for 30 s; 
final extension at 72˚C for 2 min. PCR products were visualised on 2% agarose gel with SYBR 
safe gel stain (Invitrogen). 
 
Immunohistochemistry  
Extensor digitorum muscles were dissected from postnatal day 18 mice and fixed by immersion 
in 4% paraformaldehyde in phosphate buffer for 20 min at room temperature then washed 3 
times for 10 min in phosphate buffered saline pH 7.4 (PBS) containing 0.1 M glycine.  Muscles 
were then incubated in Alexa-488 α-bungarotoxin (α-BTX; Sigma, St. Louis, MO), diluted at 
1:500 in 2% bovine serum album (BSA) with 0.2% Triton X-100 in PBS, for 30 min at room 
temperature, followed by 4 by 10 min washes in PBS. Muscles were then post-fixed in -20°C 
methanol for 5 minutes and then washed twice in PBS.  Next, the muscles were incubated 
with rabbit anti-TDP-43 antibody (Abcam) diluted 1:100 in 2% BSA with 0.2% Triton X-100 in 
PBS overnight at 4°C.  They were then washed in PBS, followed by overnight incubation in 
Alexa-568 goat anti-rabbit secondary antibody (Invitrogen) diluted 1:500 in 2% BSA and 0.2% 
Triton X-100 in PBS at 4C. Next day the muscles were washed in PBS and mounted in anti-fade 
(FlurogoldTM, Hercules, BioRad, CA).  Muscles were viewed and imaged using a Zeiss 
AxioImager Z2 fluorescence microscope. 
 
Results 
TDP-43/RNA complexes were immunoprecipitated from whole mouse brain lysates using a 
rabbit anti-TDP-43 antibody. TDP-43 immunoprecipitation (IP) was validated by western blot 
that showed TDP-43 was specifically pulled down from mouse brain lysates using the anti-TDP-
 8 
43 antibody but not with IgG (Supplemental file 2).  Purification of RNA from the isolated TDP-
43/RNA complex recovered a total of 250-350 ng of RNA from each RNA IP (RIP) experiment.  
The RIP-chip analysis of mouse brain tissue produced a list of 1,839 potential TDP-43 RNA 
targets with significant p-values (<0.05) and fold change (>2) (Supplemental file 3). The data 
from the present study was then compared to previous publications (where gene lists were 
available) to determine the extent of overlap between the TDP-43 target genes identified (Fig 1). 
The genes identified in the present study represent 17.2% of the Sephton et al. study, 17.9% of 
the Colombrita et al. study and 11.8% of the Xiao et al. study. The Arf3 gene was the only 
sequence common to all four studies. 
 
The MEME Suite program (26) was then used to identify common sequence motifs from the 150 
most highly enriched (based on fold change) TDP-43 target RNAs. The most common motif 
identified from the TDP-43 RIP-chip was (TG)n, corresponding to the known (UG)n RNA 
binding motif of TDP-43 (Fig 2A). As (TG)n is a common repeat, we also analysed RNA from 
the IgG control RIP-chip experiment (background “noise” from non-specific binding). The 
(TG)n repeat motif was not enriched among the RNAs recovered from the IgG control RIP-chip 
experiment; only an (A)n motif was identified, which corresponds to the mRNA polyA site (Fig 
2B). The frequency of the (TG)n motif within cDNA sequences was 63%. Of those genes 
containing a (TG)n motif, the location of the motif was predominantly in the 3’UTR (92%). The 
second most common motif identified was a CG-rich sequence (Fig 2C), which was primarily 
found in the 5’UTR (79%) and may simply reflect the high GC content of the promoter region. 
The motif analysis confirms the RIP-chip method is detecting true RNA targets of TDP-43, as 
the known binding motif (UG)n was the most common sequence detected.  
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Ingenuity Pathway Analysis of the TDP-43 RNA targets was used to identify biological 
functions that are potentially regulated by TDP-43. Multiple genes were related to the expected 
biological functions associated with ALS, including nervous system development and function 
and neurological disease (Table 1).  Molecular and cellular functions included RNA post-
transcriptional modification and gene expression. Analysis of Gene Ontology (GO) terms 
enriched among TDP-43 RNA binding partners revealed the top terms in each of the three GO 
term categories of cellular component, molecular function and biological process were 
synaptosome (P = 1.18 x 10-9), RNA binding (P = 6.27 x 10-21), and modification-dependent 
protein catabolic process (P = 4.46 x 10-13), respectively (see Supplemental File 4 for complete 
list). The enrichment of GO terms related to the synaptosome, suggested that TDP-43 may be 
involved in transport of mRNA and regulation of translation within presynaptic compartments. If 
TDP-43 were involved in transport of mRNA to the synapse it would be expected that TDP-43 
protein would be appropriately localised there.  In order to investigate this, localisation of the 
TDP-43 protein at the mouse neuromuscular junction was examined by immunohistochemistry. 
Analysis of the immunolabelling revealed that TDP-43 was concentrated presynaptically within 
the motor nerve terminal, directly opposite postsynaptic acetylcholine receptors (Fig 3). 
 
The TDP-43 target RNAs related to synaptic function identified in this study are shown in Table 
2, where they have been grouped into seven broad functional categories and overlap with the 
Sephton et al. (20) study has been highlighted. Thirteen genes from Table 2 were randomly 
selected for validation in an independent RIP experiment using RT-PCR (Fig 4 and 
Supplemental file 1), including seven genes associated with synaptic vesicle trafficking (top row 
of Fig 3). The gene encoding TDP-43 (Tardbp) was also included, as there is evidence that TDP-
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43 may be self-regulated. The RT-PCR results confirmed that these RNA targets were enriched 
in the TDP-43 IP RNA preparation.  
 
Discussion 
The RIP-chip analysis of mouse brain tissue provided a list of 1,839 putative RNA targets of 
TDP-43. The most common sequence detected in the 150 most abundant RNAs was the known 
TDP-43 binding motif (UG)n (Fig 2) confirming the RIP-chip method was detecting true RNA 
targets of TDP-43. Of the 1,839 genes identified in mouse brain in this study, 699 (38%) 
overlapped with those found in rat embryonic cortical neuron cultures (20).  Comparison with 
other published reports of TDP-43 RNA targets revealed a single gene was common amongst the 
four studies (Fig 1). The Arf3 gene encodes a small guanine nucleotide-binding protein that 
stimulates ADP-ribosyltransferase activity and which also plays a role in vesicular trafficking 
(28). The fact that only one gene was common to all studies is most likely due to the different 
cell/tissue types studied, as well as the fact that the two studies using neuronal cell lines (23, 24) 
only identified a relatively small number of TDP-43 targets. The Arf3 gene contains a large 
(TG)87 repeat in the 3’UTR and the corresponding mRNA has been isolated from cortical axons 
(29). Therefore, further investigation of the ARF3 gene and it’s protein in ALS and FTD is 
warranted. 
 
We hypothesise that RNPs such as TDP-43 may be playing a major role in transport of mRNAs 
along the axonal length for site-specific translation at the synapses, such as the neuromuscular 
synapse, and are crucial for fine-tuning of synaptic transmission. This proposed role for TDP-43 
regulation of local translation is supported by immunohistochemistry demonstrating that TDP-43 
is localised to the presynaptic neuromuscular junction in mouse muscle (Fig 3). In human motor 
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neurons, TDP-43 is found in the nucleus, rough endoplasmic reticulum, mitochondria, and of 
relevance to this study, in synaptic vesicles of presynaptic terminals of anterior horn neurons 
(30).  A recent report has also demonstrated that TDP-43 is actively transported in motor neuron 
axons (31), lending further support to the hypothesis that TDP-43 is involved in transport of 
RNA for local translation at presynaptic terminals. 
 
The network and gene ontology enrichment analyses conducted in this study, together with the 
localisation of TDP-43 at the presynaptic membranes (Fig 3), strongly suggest that TDP-43 may 
regulate the RNA of genes involved in synaptic transmission. Of particular interest were the 
number of genes related to synaptic vesicle docking, fusion and exocytosis (Table 2), such as 
syntaxins (Stx1b, Stx12), syntaxin binding proteins (Stxbp5, Stxbp6), synapsin (Syn2) and 
synaptophysins (Syp, Sypl1). Previous reports have shown that synaptophysin (32-37) and 
synapsin (34) both decrease in the anterior horn region of the spinal cord in ALS patients.  
Syntaxin is also decreased in the anterior horn, though to a lesser extent than synaptophysin and 
synapsin (34). The decrease in expression of synaptic vesicle proteins in the spinal cord of ALS 
patients may be due to loss of TDP-43-regulated transport of the RNA coding for these proteins. 
TDP-43 has previously been shown to be localised to RNA granules in dendrites of rat 
hippocampal neurons, and these granules also contain mRNA of known TDP-43 targets (38). 
Axons also contain mRNAs and ribosomes, and are metabolically active in synthesising proteins 
locally (39). Therefore, loss of TDP-43 mediated transport of synaptic vesicle mRNAs could 
disrupt both dendritic synapses and the neuromuscular junction. 
 
Another well-established example of altered RNA processing in motor neuron disease is loss of 
SMN protein in spinal muscular atrophy (SMA) (40). SMN plays a multifunctional role in 
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ribonucleoprotein metabolism, pre-messenger RNA splicing and RNA transport. In SMA, 
expression of presynaptic vesicle proteins such as synaptophysin, VAMP and synaptotagmin are 
decreased (41) and mouse models of SMA show evidence of impaired synaptic vesicle release at 
neuromuscular junctions (42). Similarly, impaired synaptic vesicle release, due to loss of TDP-
43-mediated transport of synaptic vesicle RNAs, may also result in muscle denervation and loss 
of motor neuron function in ALS. 
 
Mutations in ubiquitously expressed proteins like TDP-43 and SMN lead to degeneration of 
motor neurons in the CNS but not other tissues in which these proteins are expressed. Motor 
neurons may be particularly sensitive to disruptions in mRNA transport, due to their long axon 
length. Recent work from C. elegans suggests that local presynaptic translation takes place in the 
mature nervous system, and that regulating this capacity is required for the maintenance of 
synapse and axon morphology (43). In human motor neurons, synaptic terminals can be more 
than a metre removed from the nucleus. Decreased capacity to transport mRNAs into distal 
processes could jeopardise the ability to respond to injury or local stimuli within axons. In ALS, 
loss of synapse proteins may be what ultimately leads to motor neuron death. 
 
In this study we have shown that TDP-43 is localised at the presynaptic membrane of axon 
terminals of the mouse neuromuscular junction, and that over 100 RNA binding targets of TDP-
43 are associated with synaptic function. Decreased capacity to transport synaptic mRNAs into 
distal processes may be one possible mechanism that ultimately leads to motor neuron death in 
ALS.  Future experiments will be necessary to demonstrate co-localisation of identified RNA 
targets with the TDP-43 protein, within presynaptic terminals of motor neurons. 
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Figure Legends 
Figure 1. Venn diagram illustrating the number of genes in common between the present study 
and previously reported TDP-43 RNA targets.  Numbers in brackets indicate the total number of 
TDP-43 targets identified by Sephton et al. (20), Xiao et al. (23), Colombrita et al. (24) and the 
present study (Narayanan). The full list of TDP-43 binding targets identified by Polymenidou et 
al. (21) was not available for comparison. 
 
Figure 2. TDP-43 RNA targets are enriched for (UG)n repeats. The cDNA corresponding to 
RNA targets identified from TDP and control pull down were submitted to the MEME Suite.  A) 
The most common motif identified from the TDP-43 RIP-chip was (TG)n, corresponding to the 
known (UG)n RNA binding motif of TDP-43. No (TG)n repeats were identified in genes from 
the  IgG control RIP-chip experiment (B). An (A)n motif was identified, which corresponds to 
the mRNA polyA site. C) The second most common motif identified from the TDP-43 RIP-chip 
was a GC-rich sequence. 
 
Figure 3. Presynaptic localisation of TDP-43 protein at the mouse neuromuscular junction. A. 
Schematic showing the nerve terminal and muscle with presynaptic TDP-43 and postsynaptic 
acetylcholine receptors (AChRs) as in image B. Immunostaining of the extensor digitorum 
longus neuromuscular junction in C57BL/6J mice showed the presence of TDP-43 (red) in the 
presynaptic terminal and opposing acetylcholine receptors on the postsynaptic muscle (green). 
Scale bar 5 μm. 
 
Figure 4. Confirmation of TDP-43 RNA targets by reverse transcription (RT) PCR. RT-PCR 
was used to validate 14 TDP-43 targets using cDNA generated from an independent RIP 
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experiment. T = cDNA from TDP-43 RIP; C = cDNA from control IgG RIP. Genes in the top 
panel are all associated with synaptic vesicles. 
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Table 1. Top biological functions associated with TDP-43 target RNAs, identified using 
Ingenuity Pathway Analysis. 
 
Function  p-value # of genes 
Disease and disorders 
Neurological disease 3.38  x 10-13 492 
Genetic disorder 1.31  x 10-12 767 
Skeletal and muscular disorders 1.31  x 10-12 356 
Molecular and cellular functions 
RNA post-transcriptional modification 3.74  x 10-21 96 
Gene expression 1.57  x 10-17 355 
Post-translational modification 2.74  x 10-14 187 
Physiological and developmental function 
Nervous system development and function 5.88 x 10-6  162 
Connective tissue development and function 1.91  x 10-5 108 
Tissue development 6.10  x 10-5 128   
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Table 2. TDP-43 target genes associated with synaptic function.  Symbols in bold text represent 
TDP-43 target genes also reported by Sephton et al. (20). 
Gene 
Symbol 
Gene Name Gene 
Symbol 
Gene Name 
SYNAPTIC VESICLE ASSOCIATED PROTEINS ION CHANNELS & TRANSPORTERS 
Cadm1 Cell adhesion molecule 1 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 
Cadps Calcium-dependent secretion activator Atp2b2 ATPase calcium-transporting plasma membrane 2 
Dmxl2 Dmx-like 2 Cacnb4 Calcium channel voltage-dependent beta-4 subunit 
Esyt2 Extended synaptotagmin-like protein 2 Kcnd2 Potassium voltage-gated channel Shal-related 
subfamily member 2 
Napb NSF attachment protein beta Gabra1 Gamma-aminobutyric acid receptor subunit alpha-1 
Snapin SNAP-associated protein Gabra2 Gamma-aminobutyric acid receptor subunit alpha-2 
Snca Alpha synuclein Gabra5 Gamma-aminobutyric acid receptor subunit alpha-5 
Stx12 Syntaxin 12 Gabrb2 Gamma-aminobutyric acid receptor subunit beta-2 
Stx1b Syntaxin 1B Gabrb3 Gamma-aminobutyric acid receptor subunit beta-3 
Stxbp5 Syntaxin-binding protein 5 Glra2 Glycine receptor subunit alpha-2 
Stxbp6 Syntaxin-binding protein 6 Glrb Glycine receptor subunit beta 
Syap1 Synapse-associated protein 1 Gria2 Glutamate receptor 2 
Sybu Syntabulin (syntaxin-interacting) Gria3 Glutamate receptor 3 
Syn2 Synapsin-2 Gria4 Glutamate receptor 4 
Syp Synaptophysin STRUCTURAL PROTEINS 
Sypl1 Synaptophysin-like protein 1 Actr3 Actin-related protein 3 
Vamp3 Vesicle-associated membrane protein 3 Ank3 Ankyrin 3 
SIGNAL TRANSDUCTION Apc Adenomatous polyposis coli 
Anks1b Ankyrin repeat and sterile alpha motif 
domain-containing protein 1B 
Bsn Bassoon 
Bdnf Brain-derived neurotrophic factor Cald1 Caldesmon 1 
Cav2 Caveolin-2 Dlg1 Disks large homolog 1 
Cbln4 Cerebellin-4 Dmd Dystrophin 
Fbxo45 F-box/SPRY domain-containing protein 1 Gphn Gephyrin 
Gap43 Neuromodulin Kif3a Kinesin family member 3A 
Homer1 Homer protein homolog 1 Lin7a Lin-7 homolog A 
Lphn2 Latrophilin-2 Lin7c Lin-7 homolog C 
Lrrtm2 Leucine-rich repeat transmembrane neuronal 
protein 2 
Myo5a Myosin Va 
Pcdh8 Protocadherin-8 Nefl Neurofilament light polypeptide 
Pdzrn3 PDZ domain-containing RING finger 
protein 3 
Sept3 Septin 3 
Strn Striatin, calmodulin binding protein Sept7 Septin 7 
Sumo1 SMT3 suppressor of mif two 3 homolog 1 Sept11 Septin 11 
Wnt5a Protein Wnt-5a Syne1 Synaptic nuclear envelope 1 
Ywhaz 14-3-3 protein zeta/delta GTPASE SIGNALLING 
ENZYME ACTIVITY Abi1 Abl interactor 1 
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Akap5 A-kinase anchor protein 5 Chn2 Chimerin 2 
Camk2d Calcium/calmodulin-dependent protein 
kinase type II delta chain 
Erc2 ERC protein 2 
Cask Calcium/calmodulin-dependent serine 
protein kinase 
Gopc Golgi-associated PDZ and coiled-coil motif-
containing protein 
Epha4 Ephrin type-A receptor 4 Gnai1 Guanine nucleotide-binding protein G(i), alpha-1 
subunit 
Epha7 Ephrin type-A receptor 7 Gnas Guanine nucleotide-binding protein alpha subunit  
Gad2 Glutamate decarboxylase 2 Kras GTPase Kras 
Gls Glutaminase Rab11a Ras-related protein Rab-11A 
Gsk3b Glycogen synthase kinase-3 beta Rab14 Ras-related protein Rab-14 
Hnmt Histamine N-methyltransferase Rab5a Ras-related protein Rab-5A 
Lnpep Leucyl-cystinyl aminopeptidase Rasgrp2 RAS guanyl-releasing protein 2 
Mdm2 E3 ubiquitin-protein ligase Mdm2 Sos1 Son of sevenless homolog 1 
Pik3r1 phosphoinositide-3-kinase, regulatory 
subunit 1 
RNA PROCESSING 
Ppfia2 Protein tyrosine phosphatase, receptor type, 
f polypeptide interacting protein (liprin), 
alpha 2 
Cpeb1 Cytoplasmic polyadenylation element-binding 
protein 1 
Ppp3ca Protein phosphatase 3 catalytic subunit alpha Cript Cysteine-rich PDZ-binding protein 
Ptgs2 Prostaglandin G/H synthase 2 Egr1 Early growth response protein 1 
Rps6kb1 Ribosomal protein S6 kinase beta-1 Fos FBJ osteosarcoma oncogene 
Sh3kbp
1 
SH3 domain-containing kinase-binding 
protein 1 
Mef2c Myocyte enhancer factor 2C 
Ube2v2 Ubiquitin-conjugating enzyme E2 variant 2 Neurod2 Neurogenic differentiation 2 
Usp14 Ubiquitin carboxyl-terminal hydrolase 14 Pja2 Praja ring finger 2 
Usp46 Ubiquitin carboxyl-terminal hydrolase 46 Syncrip Synaptotagmin binding, cytoplasmic RNA 
interacting protein   
